Drug Profile
Meningococcal infections vaccine - Pfizer
Alternative Names: MenABCWY - Pfizer; PENBRAYA™; PF-06886992Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Meningococcal infections
Most Recent Events
- 05 Jan 2024 Pfizer completes a phase IIb trial in Meningococcal infections (In children, In adolescents, Prevention) in USA (IM) (NCT04440176) (EudraCT2019-004923-19)
- 20 Oct 2023 Registered for Meningococcal infections (In adolescents, In children, Prevention, In adults) in USA (IM)
- 18 Jan 2023 Pfizer terminates a phase II trials in Meningococcal infections (In infants, Prevention) in Spain, Germany and Greece (IM) due to sponsor's decision (EudraCT2020-000948-60) (NCT04645966)